Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma. by Seargent,  J.M. et al.
Durham Research Online
Deposited in DRO:
12 February 2013
Version of attached file:
Accepted Version
Peer-review status of attached file:
Peer-reviewed
Citation for published item:
Seargent, J.M. and Loadman, P.M. and Martin, S.W. and Naylor, B. and Bibby, M.C. and Gill, J.H. (2005)
’Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma.’, Urology., 65 (4).
pp. 815-820.
Further information on publisher’s website:
http://dx.doi.org/10.1016/j.urology.2004.11.016
Publisher’s copyright statement:
NOTICE: this is the authors version of a work that was accepted for publication in Urology. Changes resulting from
the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control
mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted
for publication. A definitive version was subsequently published in Urology, 65/4, 2005, 10.1016/j.urology.2004.11.016
Additional information:
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for
personal research or study, educational, or not-for-profit purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in DRO
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full DRO policy for further details.
Durham University Library, Stockton Road, Durham DH1 3LY, United Kingdom
Tel : +44 (0)191 334 3042 — Fax : +44 (0)191 334 2971
http://dro.dur.ac.uk
1Expression of MMP-10 in Human Transitional-Cell Carcinoma of 
the Bladder 
Jill M. Seargent1, Paul M. Loadman1, Sandie W. Martin1, Brian Naylor2, 
Michael C. Bibby1, Jason H. Gill1* 
1Cancer Research UK Laboratories, Tom Connors Cancer Research Centre, 
University of Bradford, Bradford, BD7 1DP, UK 
2Department of Histopathology, Bradford Royal Infirmary, Bradford, BD9 6RJ, UK 
*To whom correspondence should be addressed at: 
 Dr JH Gill, Cancer Research UK Laboratories, Tom Connors Cancer Research 
Centre, University of Bradford, Bradford, BD7 1DP, United Kingdom. 
Phone: +44(0)1274 233232; Fax: +44(0)1274 233234; E-mail: j.gill1@bradford.ac.uk 
Running Title: MMP-10 in Bladder Cancer 
Keywords: Matrix Metalloproteinase, bladder cancer, Stromelysin, MMP10 
Acknowledgements
The authors would like to thank Miss B. Cronin for technical help with this study and 
members of the Tom Connors Cancer Research Centre for critical reading of the 
manuscript. 
This work was supported by Cancer Research UK, grant number  C459/A2579 
2Introduction 
In order that malignant tumors can grow, spread and metastasise they must possess 
the potential to degrade and remodel both the extracellular matrix (ECM) and 
basement membranes, promote an angiogenic response, evade immune surveillance 
and avoid elimination 1.  Multiple proteolytic enzymes have been demonstrated to be 
involved in these processes, most prominent among which are the matrix 
metalloproteinases (MMPs) 1,2.  The MMPs are a family of at least 24 structurally 
related zinc-dependent endopeptidases central to tumor invasion, metastasis, 
angiogenesis and malignant cell proliferation 1,3,4. Most MMPs, with the exception of 
the membrane type MMPs (MT-MMPs), are secreted as inactive zymogens 
(proMMPs) which must be subsequently activated extracellularly to generate 
catalytically active MMP 1,5,6.  
Compared to other MMPs, MMP-10 has a relatively broad substrate 
specificity which, in addition to activation of proMMPs –1, -7, -8, -9 and –13 5,6, 
includes several ECM proteins1,7,8. Overexpression of MMP-10 has been 
demonstrated in several human tumors of epithelial origin including lung, head and 
neck, oesophageal and oral squamous cell carcinoma and squamous and basal cell 
carcinomas of the skin 9-13.  Unlike several other MMPs which are localised 
predominantly in tumor stroma 13,14, tumor cells themselves appear to express MMP-
10 6,9,13,15.  The expression profile of MMP-10 in several tumor types and localization 
of MMP-10 predominantly to tumor cells coupled with a broad substrate specificity 
strongly supports MMP-10 as a valid target for therapeutic intervention 7-9,11-13. 
 Bladder cancer is the fourth most common cancer in men, with an incidence of 
7,880 new diagnoses in the UK in 2000 and a mortality of 3,230 in 2002 16,17.   
Transitional cell carcinoma (TCC) accounts for approximately 90% of all bladder 
3cancers and is classified as either a superficial (Ta and T1) or muscle invasive (≥ T2) 
stage. Although superficial TCC generally has a good prognosis compared to muscle 
invasive disease, approximately 70% of superficial tumors recur, with about 20% of 
these recurring as aggressive invasive disease 16. A better understanding of the 
molecular pathology of TCC and prediction of tumor behaviour are central to 
improving diagnosis, clinical surveillance and treatment. 
Several studies have addressed the expression of MMPs in TCC with the aim 
of ascertaining their role in tumor progression, value as prognostic markers and 
potential as therapeutic targets. Elevated levels of MMP-2, -9, -11 and –13 have all 
been reported in invasive compared to superficial TCC 18-20. MMP-2 and –9 are 
detectable in urine 21,22 and are associated with tumor stage and a poor prognosis 23,24.  
On the basis of findings so far, the involvement and roles of individual MMPs in TCC 
of the bladder seem to be complex and unclear. In the present study, we investigated 
the expression of MMP-10 by immunohistochemistry using tissue microarrays 
(TMAs) to determine any correlation between MMP-10 and clinicopathological 
factors and assess the potential of MMP-10 as a therapeutic target for human bladder 
cancer. 
MATERIALS AND METHODS 
Human tissues
A total of 60 formalin-fixed, paraffin-embedded specimens of human bladder 
transitional cell carcinoma (TCC) were used for this study. The study also includes 10 
histologically normal human bladder tissue specimens, excised from patients with 
early stage TCC but distant to the tumor mass. Tumors were representative of all 
grades (11 Grade 1; 32 Grade 2; 17 Grade 3) of both superficial (20 pTa; 18 pT1) and 
4muscle-invasive (22 ≥pT2) stages of human bladder TCC. 52 of the tumor blocks were 
used as tissue microarrays (TMAs). All normal human bladder blocks (n = 10) and 20 
tumor blocks, inclusive of 12 blocks also used for TMA construction, were used for 
conventional immunohistochemistry. All experiments were performed after first 
obtaining consent from the local research and ethics committee according to Medical 
Research Council regulations. Patient details were anonymised to ensure 
confidentiality. 
Cell culture and protein isolation
The human bladder tumor cell lines EJ138 and RT112 (National Cancer Institute, 
Frederick, MD) were cultured in RPMI supplemented with 10% foetal bovine serum 
and L-glutamine (2mM).  Before confluence, cells were lysed in RIPA buffer, 
sonicated (3 x 15 s, 4°C) and centrifuged at 10,000 x g.  Protein concentrations of the 
resultant supernatants were determined using the BioRad protein assay (BioRad, UK). 
SDS-PAGE and western blotting 
Cell lysates (30 µg protein per lane), recombinant MMP-3 (100 ng; R&D systems, 
UK) and recombinant MMP-10 (100 ng; R&D systems) were separated on SDS-
polyacrylamide gels (10%) and proteins transferred to polyvinylidenedifluoride 
(PVDF) membrane (Hybond-P; Amersham, UK). Non-specific protein binding was 
blocked (2% ECL advanced blocking reagent; Amersham), blots were incubated with 
a monoclonal antibody, raised against human MMP-10 (5E4, Novocastra, UK; diluted 
1:1000) at 4°C overnight. Immunoreactive bands were localised using an HRP-
conjugated secondary antibody and visualised using an enhanced chemiluminescence 
(ECL) detection kit (Amersham). For antigenic adsorption, the primary antibody was 
5incubated with a two-time excess of recombinant MMP-10 protein (R&D systems, 
UK) overnight at 4°C prior to being incubated with the blot.   
Tissue microarray construction 
TMAs were constructed from paraffin embedded blocks to represent the various 
grades (G1-G3) and the various stages (pTa, pT1, pT2) of human bladder TCC.  TMA 
construction was achieved using a Beecher Instruments microarrayer (Silver Spring, 
MD, USA) using a modified method of that by Bubendorf et al. 25. Briefly, cylindrical 
cores (600 µM) were punch-biopsied from representative areas of each donor block 
and transferred into a recipient block. Tissue sampling used four cores from each 
tumor block to provide representative data on each parent block 26. A total of 108 core 
samples representing 26 patients were included per TMA block, of which two were 
constructed (total of 52 patients). Sections, 5 µM thick, were cut from the TMA 
blocks and mounted using a tape transfer system (Instrumedics, USA). H&E staining 
for verification of histology and sample integrity was performed on the first and every 
subsequent tenth TMA section.  TMA slides were then subject to 
immunohistochemical analyses. 
Immunohistochemistry 
Localization of MMP-10 was assessed by immunohistochemistry of human bladder 
TCC and histologically normal bladder tissue, as previously described in our 
laboratory 9. Following inhibition of non-specific antibody binding, sections were 
incubated for 90 min at room temperature with primary antibody (5E4; diluted 1:50). 
Controls were performed using normal mouse IgG instead of primary antibody. 
Immunoreactivity was detected using an anti-mouse biotinylated secondary antibody 
6(Vector Laboratories, USA; diluted 1:200), followed by amplification and detection 
using a Vectastain ABC kit (Vector Laboratories) and 3,3’-diaminobenzidine (DAB). 
Sections were then counterstained with Harris’ hematoxylin and mounted in DPX 
mountant (Sigma, UK).  
Semi-quantitative analysis of immunohistochemistry 
Positive immunostaining was scored semi-quantitatively by two independent 
observers. Each TMA core was scored for intensity and extent of MMP-10 in the 
epithelial compartment on a scale from 0 (no staining) to 4 (maximal staining). An 
average score was then calculated for each tumor of the TMA. Whole sections were 
analysed in the same manner and assigned a score using the same scale. In cases 
where both TMA and whole sections were available (n=12), average expression in the 
TMA was compared to that of whole sections. In all cases, MMP-10 expression was 
compared for any relationships to clinicopatholigical parameters. 
Statistical analysis 
Statistical analyses were performed using SPSS statistical software.  Because 
expression of MMP-10 is not normally distributed, the average values for each group 
of patients were reported as medians with interquartile ranges. Statistical analyses 
were performed using non-parametric tests (Mann-Whitney U-test and Kruskal-
Wallis).  Values of P less than 0.05 in two-tailed analyses were considered significant. 
RESULTS 
Specificity of antibody against MMP-10 
7Using western blotting. the antibody detected bands at approximately 52 kD (pro-
MMP-10) and 44 kD (active MMP-10) with recombinant MMP-10. No bands were 
detected with recombinant MMP-3, the closest structural homologue to MMP-10 
(Figure 1A).  Antibody specificity and suitability for use in immunohistochemistry 
was provided by the detection of both pro- and active-MMP-10 in the EJ138 and 
RT112 human bladder cell lines (Figure 1A).  Antigenic adsorption of this antibody 
using recombinant MMP-10 protein considerably diminished detection of MMP-10 
by western blotting (data not shown), further proving the MMP-10 specificity of this 
antibody.   
Expression of MMP-10 in bladder cancer 
Immunohistochemical analyses were used to evaluate the expression of MMP-10 
protein in human bladder TCC. Studies using TMAs had been shown previously to be 
highly representative of results obtained from whole histological sections 27. This 
observation was also mirrored in our study, with a very close agreement of expression 
in the 12 specimens analysed by both TMA and as whole sections (shown in figure 1 
B-G).  MMP-10 was present in all superficial (pTa, pT1; n=38) tumors and 19/22 
muscle invasive (≥pT2) tumors.  In all cases, MMP-10 was predominantly localised in 
the tumor epithelia rather than the stroma (Figure 1).  Occasionally weak MMP-10 
expression was also detected within the stroma of a small subset of tumors, in general, 
MMP-10 was expressed by tumor cells.   
 Although expression of MMP-10 was observed in histologically normal 
bladder tissue (Table 1), significantly higher levels were observed in TCC (Table 1). 
No significant difference in expression was observed between stages pTa and pT1 of 
superficial TCC (Table 2; P = 0.964).  Conversely, a significant difference was 
8observed between superficial non-muscle invasive (pTa, pT1) and muscle invasive 
(≥pT2) TCC (Table 2; P = 0.014), MMP-10 expression being lower in the muscle 
invasive tumors (Table 1).  Interestingly, unlike many MMPs, no correlation is 
observed between MMP-10 expression and the invasive potential of bladder TCC.  
Expression of MMP-10 in histologically normal bladder tissue is not significantly 
different from that observed in tumors demonstrating invasion into the muscle layer 
(≥pT2 stage) (Table 2; P = 0.50). 
High levels of MMP-10 were observed in all tumor grades (degree of cellular 
differentiation) in comparison to normal bladder (Table 1).  Although expression 
appeared to show a negative correlation to tumor grade (Table 1), this was not 
statistically significant (Table 2, P = 0.379).  Interestingly, expression in 
histologically normal bladder tissue was significantly different from grade 1 (Table 2; 
P = 0.02) but not grade 2 or 3 tumors (Table 2), supporting MMP-10 as an early event 
in bladder tumorigenesis. The lack of difference in expression between tumor grades 
suggest that MMP-10 does not strongly associate with the differentiation status of the 
tumor (Table 2). 
Comment 
Breakdown and remodelling of the ECM is essential for tumor growth, 
survival and invasion.  Although involving many enzymes, the MMPs are believed to 
be the central mediators of these processes.  In this study, MMP-10 was expressed at 
much higher levels in human bladder TCCs than normal bladder.  In contrast to other 
MMPs, MMP-10 localises predominantly to the tumor epithelial mass rather than the 
tumor stroma 28. This epithelial localization is substantiated by similar observations in 
human skin carcinomas 13 and our studies in lung carcinomas 9.  With reference to 
9bladder carcinoma, MMP-13 expression is also predominantly in the tumor cells 
rather than tumor stroma 20.  In contrast to MMP-13 which is restricted to cells at the 
invading edge 20, MMP-10 was expressed strongly throughout the tumor, suggesting it 
has a role in bladder tumorigenesis but may not be directly related to muscular 
invasion, unlike MMP-13. 
 Converse to the majority of MMPs, which show tight affiliation with tumor 
invasion, we have demonstrated an inverse relationship between MMP-10 expression 
and muscle invasive potential.  Although MMP-10 levels were significantly higher in 
superficial TCC compared to normal tissue, levels were significantly lower in muscle-
invasive disease.  In addition, a weak negative trend was observed between MMP-10 
and tumor grade, suggesting MMP-10 overexpression as an early event in bladder 
tumorigenesis. These data strongly suggest that MMP-10 is involved in the expansion 
of the neoplastic cell mass rather than invasion or progression to metastatic disease. 
The recent crystallization of the catalytic site of MMP-10 29 hopefully will lead to the 
development of a specific inhibitor to address and resolve this theory. 
 Recently, a close relationship has been suggested between expression of 
MMP-10 and laminin-5, an ECM protein central to cell migration and cell adhesion 
30,31
. Interestingly, enhanced loss from the basement membrane of laminin-5 occurs 
early in urothelial cell carcinoma, is associated with development of an invasive 
tumor phenotype and reorganization of the ECM at the invasive tumor front 31. 
Although co-expression of these proteins are often observed, the interplay between 
MMP-10 and laminin-5 has not yet been shown in vivo31. Therefore it is conceivable 
to suggest that MMP-10 may be involved in laminin-5 reorganization and thus cell 
motility and tumor expansion. 
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Over the last few years, the identification of MMPs as being tumor specific 
and necessary for metastasis has resulted in the development of MMP inhibitors as 
anticancer therapeutics.  Until recently, clinical trials using these inhibitors have been 
disappointing with very little success 3.  The failure of these drugs was attributed to 
their broad spectrum of MMP inhibition, activity against normal cells and use in late-
stage cancer clinical trials, which bypasses MMPs involved earlier in tumorigenesis, 
such as MMP-10 3,32. A greater understanding of MMP expression, their activity 
profiles and interrelationships is required in order to design better MMP mediated 
anticancer therapeutics 3,32. 
Conclusions 
This is the first study showing expression of MMP-10 in human TCC of the bladder.  
Unlike the majority of MMPs, MMP-10 appears to be an early event in TCC growth 
and development and does not relate to specifically to tumor invasion. Further 
evaluation of MMP-10 in the bladder is required to address levels of active enzyme, 
relationship to prognosis and its viability as a target for therapeutic intervention in 
human TCC of the bladder. 
11
References 
1. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in 
cancer progression. Nat Rev Cancer. 2: 161-74, 2002. 
2. Duffy MJ and McCarthy K: Matrix metalloproteinases in cancer: prognostic 
markers and targets for therapy (review). Int J Oncol. 12: 1343-8, 1998. 
3. Overall CM and Lopez-Otin C: Strategies for MMP inhibition in cancer: 
innovations for the post-trial era. Nat Rev Cancer. 2: 657-72, 2002. 
4. Stamenkovic I: Extracellular matrix remodelling: the role of matrix 
metalloproteinases. J Pathol. 200: 448-64, 2003. 
5. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL and 
Quigley JP: Activation of matrix metalloproteinase-9 (MMP-9) via a 
converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J 
Biol Chem. 274: 13066-76, 1999. 
6. Nakamura H, Fujii Y, Ohuchi E, Yamamoto E and Okada Y: Activation of the 
precursor of human stromelysin 2 and its interactions with other matrix 
metalloproteinases. Eur J Biochem. 253: 67-75, 1998. 
7. Vihinen P and Kahari VM: Matrix metalloproteinases in cancer: prognostic 
markers and therapeutic targets. Int J Cancer. 99: 157-66, 2002. 
8. Duffy MJ, Maguire TM, Hill A, McDermott E and O'Higgins N: 
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. 
Breast Cancer Res. 2: 252-7, 2000. 
9. Gill J, Kirwan I, Seargent J, Martin S, Tijani S, Anikin V, Mearns A, Bibby 
M, Anthoney A and Loadman P: MMP-10 is overexpressed, proteolytically 
active and a potential target for therapeutic intervention in human lung 
carcinomas. Neoplasia. in press, 2004. 
10. Impola U, Uitto VJ, Hietanen J, Hakkinen L, Zhang L, Larjava H, Isaka K and 
Saarialho-Kere U: Differential expression of matrilysin-1 (MMP-7), 92 kD 
gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and 
squamous cell cancer. J Pathol. 202: 14-22, 2004. 
11. O-Charoenrat P, Rhys-Evans PH and Eccles SA: Expression of matrix 
metalloproteinases and their inhibitors correlates with invasion and metastasis 
in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head 
Neck Surg. 127: 813-20, 2001. 
12. Mathew R, Khanna R, Kumar R, Mathur M, Shukla NK and Ralhan R: 
Stromelysin-2 overexpression in human esophageal squamous cell carcinoma: 
potential clinical implications. Cancer Detect Prev. 26: 222-8, 2002. 
13. Kerkela E, Ala-aho R, Lohi J, Grenman R, V MK and Saarialho-Kere U: 
Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) 
expression in epithelial skin cancers. Br J Cancer. 84: 659-69, 2001. 
14. Foda HD and Zucker S: Matrix metalloproteinases in cancer invasion, 
metastasis and angiogenesis. Drug Discov Today. 6: 478-482, 2001. 
15. Muller D, Breathnach R, Engelmann A, Millon R, Bronner G, Flesch H, 
Dumont P, Eber M and Abecassis J: Expression of collagenase-related 
metalloproteinase genes in human lung or head and neck tumours. Int J 
Cancer. 48: 550-6, 1991. 
16. Cancer Research UK: CancerStats Report: Bladder cancer, 2002. 
12
17. Cancer Research UK: Cancer Statistics: http://www.cancerresearchuk.org, 
June 2004. 
18. Sumi T, Yoshida H, Hyun Y, Yasui T, Matsumoto Y, Hattori K, Sugimura K, 
Kawashima H, Nakatani T and Ishiko O: Expression of matrix 
metalloproteinases in human transitional cell carcinoma of the urinary bladder. 
Oncol Rep. 10: 345-9, 2003. 
19. Nutt JE, Durkan GC, Mellon JK and Lunec J: Matrix metalloproteinases 
(MMPs) in bladder cancer: the induction of MMP9 by epidermal growth 
factor and its detection in urine. BJU Int. 91: 99-104, 2003. 
20. Bostrom PJ, Ravanti L, Reunanen N, Aaltonen V, Soderstrom KO, Kahari VM 
and Laato M: Expression of collagenase-3 (matrix metalloproteinase-13) in 
transitional-cell carcinoma of the urinary bladder. Int J Cancer. 88: 417-23, 
2000. 
21. Bianco FJ, Jr., Gervasi DC, Tiguert R, Grignon DJ, Pontes JE, Crissman JD, 
Fridman R and Wood DP, Jr.: Matrix metalloproteinase-9 expression in 
bladder washes from bladder cancer patients predicts pathological stage and 
grade. Clin Cancer Res. 4: 3011-6, 1998. 
22. Monier F, Surla A, Guillot M and Morel F: Gelatinase isoforms in urine from 
bladder cancer patients. Clin Chim Acta. 299: 11-23, 2000. 
23. Vasala K, Paakko P and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 
immunoreactive protein as a prognostic marker in bladder cancer. Urology.
62: 952-7, 2003. 
24. Miyata Y, Kanda S, Nomata K, Hayashida Y and Kanetake H: Expression of 
metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of 
metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: 
correlation with tumor stage and survival. Urology. 63: 602-8, 2004. 
25. Bubendorf L, Nocito A, Moch H and Sauter G: Tissue microarray (TMA) 
technology: miniaturized pathology archives for high-throughput in situ 
studies. J Pathol. 195: 72-9, 2001. 
26. Hoos A and Cordon-Cardo C: Tissue microarray profiling of cancer specimens 
and cell lines: opportunities and limitations. Lab Invest. 81: 1331-8, 2001. 
27. Nocito A, Bubendorf L, Maria Tinner E, Suess K, Wagner U, Forster T, 
Kononen J, Fijan A, Bruderer J, Schmid U et al.: Microarrays of bladder 
cancer tissue are highly representative of proliferation index and histological 
grade. J Pathol. 194: 349-57, 2001. 
28. Nakopoulou L, Gakiopoulou H, Zervas A, Giannopoulou I, Constantinides C, 
Lazaris AC, Liapis H, Kyriakou G and Dimopoulos C: MMP-3 mRNA and 
MMP-3 and MMP-1 proteins in bladder cancer: a comparison with 
clinicopathologic features and survival. Appl Immunohistochem Mol 
Morphol. 9: 130-7, 2001. 
29. Bertini I, Calderone V, Fragai M, Luchinat C, Mangani S and Terni B: Crystal 
structure of the catalytic domain of human matrix metalloproteinase 10. J Mol 
Biol. 336: 707-16, 2004. 
30. Rechardt O, Elomaa O, Vaalamo M, Paakkonen K, Jahkola T, Hook-Nikanne 
J, Hembry RM, Hakkinen L, Kere J and Saarialho-Kere U: Stromelysin-2 is 
upregulated during normal wound repair and is induced by cytokines. J Invest 
Dermatol. 115: 778-87, 2000. 
31. Hindermann W, Berndt A, Haas KM, Wunderlich H, Katenkamp D and 
Kosmehl H: Immunohistochemical demonstration of the gamma2 chain of 
13
laminin-5 in urinary bladder urothelial carcinoma. Impact for diagnosis and 
prognosis. Cancer Detect Prev. 27: 109-15, 2003. 
32. Kannan R, Ruff M, Kochins JG, Manly SP, Stoll I, El Fahime M, Noel A, 
Foidart JM, Rio MC, Dive V et al.: Purification of active matrix 
metalloproteinase catalytic domains and its use for screening of specific 
stromelysin-3 inhibitors. Protein Expr Purif. 16: 76-83, 1999. 
14
Figure 1: (A) Immunoblot of human MMP-10 demonstrating antibody specificity. 
The antibody detects both pro- and active MMP-10. No cross reactivity was observed 
against MMP-3. (B-G) Expression of MMP-10 in human transitional cell carcinoma 
(TCC) of human bladder by immunohistochemical analyses.  (B, D) demonstrate 
MMP-10 expression in full histological sections and (C, E) demonstrate MMP-10 
expression in the same tissue within the TMA, respectively. (B, C) pTa grade 1 TCC, 
(section expression score = 4, TMA score = 4.0); (D, E) pT1 grade 3 TCC, (section 
expression score =4, TMA score range = 3.0-4.0). (F) Expression of MMP-10 in 
histologically normal bladder tissue (expression score = 2). (G) Expression of MMP-
10 in muscle invasive pT2 grade 2 TCC (expression score =1). Scale bars are included 
in each image.  
Table 1
Expression of MMP-10 protein expression in human TCC of the bladder.
Characteristic Number of 
Patients
Median immunohistochemical score
(interquartile range)
Tumor Stage
Normal Bladder 10 2.00  (2.00-3.00)
  pTa 20 3.11  (2.94-3.54)
  pT1 18 3.14  (2.67-3.90)
≥ pT2 22 2.50  (1.00-3.33)
Tumor Grade
Normal Bladder 10 2.00  (2.00-3.00)
G1 11 3.11  (3.00-3.90)
G2 32 3.00  (2.50-3.70)
G3 17 2.88  (2.60-3.60)
Table 2
Comparison of MMP-10 expression with clinicopathological features in human 
bladder TCC
Clinicopathological feature Median MMP-10
scores
Difference in  MMP-10
expression ( P value)
Tumor stage 0.003
a
pTa pT1 3.11 / 3.14 0.964
b
pTa ≥ pT2 3.11 / 2.50 0.008
pT1 ≥ pT2 3.11 / 2.50 0.005
Normal Superficial 2.00 / 3.11 0.010
Superficial Invasive 3.11 / 2.50 0.014
Normal Invasive 2.00 / 2.50  0.500
b
Tumor Grade   0.379
ab
Normal Grade 1 2.00 / 3.11  0.020
Normal Grade 2 2.00 / 3.00  0.100
b
Normal Grade 3 2.00 / 2.88 0.130
b
Grade 1 Grade 2 3.11 / 3.00  0.174
b
Grade 1 Grade 3 3.11 / 2.88  0.329
b
Grade 2 Grade 3 3.00 / 2.88  0.747
b
a
 Determined by Kruskal-Wallis one-way analysis
b
Not Significant
Superficial: Non-muscle invasive human bladder carcinoma, combined pTa and pT1;
Invasive: Muscle invasive human bladder carcinoma, ≥ pT2.

